Manufacturer
PFIZER (PERTH) PTY. LTD.
Contents
Doxorubicin HCl
Indication
Regression in neoplastic conditions eg, acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue & bone sarcomas, hepatomas, breast, bronchogenic (lung), thyroid & ovarian carcinoma, Hodgkin's & non-Hodgkin's type lymphomas. Intravesically in the primary management of non-metastatic bladder carcinoma.
Instruction
Adult & ped 60-75 mg/m2 as single IV inj at 21-day intervals or 30 mg/m2 on each of 3 successive days repeated every 4 wk. Cumulative lifetime dose limit: 550 mg/m2. Intra-arterial infusion 45-100 mg/m2 for 1-3 days. Adult ≥70 yr Total cumulative dose: 450 mg/m2.
Drug interaction
Increased conc & clinical effect by CYP3A4, CYP2D6 &/or P-glycoprotein (P-gp) inhibitors (eg, verapamil); decreased conc by CYP3A4 (eg, phenobarb, phenytoin, St. John's wort) & P-gp inducers. Additive toxicity w/ other cytotoxic agents. Sensitizes heart to doxorubicin cardiotoxicity w/ concurrent cyclophosphamide treatment & may exacerbate cyclophosphamide cystitis. Increased AUC by cyclosporin. May form precipitate w/ heparin & fluorouracil. Enhanced myocardial toxicity w/ mediastinal radiotherapy. Increased plasma conc by paclitaxel. Additive cardiotoxic effect w/ propranolol. Increased radiation toxicity ie, skin reactions & mucositis w/ radiotherapy.
Malaysia
